Lapatinib

Lapatinib

• CAS Number: 231277-92-2
• UNSPSC Description: Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].
• Target Antigen: Autophagy; EGFR; Ferroptosis
• Type: Reference compound
• Related Pathways: Apoptosis;Autophagy;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/Lapatinib.html
• Purity: 99.83
• Solubility: DMSO : 125 mg/mL (ultrasonic)
• Smiles: O=S(CCNCC1=CC=C(C2=CC=C3C(C(NC4=CC(Cl)=C(C=C4)OCC5=CC(F)=CC=C5)=NC=N3)=C2)O1)(C)=O
• Molecular Weight: 581.06
• References & Citations: [1]Rusnak DW, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001 Dec;1(2):85-94ACS Chem Biol. 2016 Apr 15;11(4):992-1000.|ACS Omega. March 3, 2022.|Acta Pharmacol Sin. 2021 Jan;42(1):108-114.|Adv Sci (Weinh). 2022 Dec 23;e2203884.|Analyst. 2017 Jan 26;142(3):525-536. |Biochim Biophys Acta Mol Basis Dis. 2024 Aug 9:167458.|Biol Proced Online. 2023 Jun 27;25(1):19.|Biomedical Engineering Advances. June 2022, 100040.|bioRxiv. 2019 Sep.|bioRxiv. 2021 Jan 9.|bioRxiv. 2024 Nov 6:2024.11.04.621884.|Biotechnol Bioeng. 2021 Sep 3.|Br J Cancer. 2021 Nov 24.|Cancer Chemother Pharmacol. 2018 Sep;82(3):383-394.|Cancer Lett. 2020 Apr 10;475:53-64.|Cancer Lett. 2021 Apr 28;504:125-136.|Cancer Lett. 2021 Jun 18.|Cancer Lett. 2024 Jun 5:217008.|Cancers (Basel). 2022, 14(23), 5854|Cancers (Basel). 2024 Apr 25;16(9):1651.|Carcinogenesis. 2022 Sep 30;bgac078.|Cell Mol Life Sci. 2023 Mar 18;80(4):100.|Cell Physiol Biochem. 2015;37(6):2275-87.|Cell Rep Methods. 2023 Oct 23;3(10):100599.|Cell Syst. 2020 Nov 18;11(5):478-494.e9.|Clin Chim Acta. 2018 Oct;485:298-304.|Clin Transl Med. 2020 Aug;10(4):e148.|Drug Des Devel Ther. 2020 Feb 25;14:783-793.|Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11.|Eur J Med Chem. 2019 Aug 15;176:393-409.|Exp Cell Res. 2020 Aug 1;393(1):112054.|Front Immunol. 2023 Mar 17.|Front Oncol. 2021 Mar 26;11:608201.|Front Pharmacol. 2021 Mar 8;12:644342.|Fundam Clin Pharmacol. 2021 Feb 1.|Gene. 2022 Jan 10;146171.|Head Neck. 2023 May 15.|iScience. 2023 Oct 3.|J Biol Chem. 2022 Jul 31;102310.|J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Feb 27;1049-1050:30-40.|J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Mar 26:1237:124100.|J Exp Clin Cancer Res. 2018 Jun 25;37(1):123.|J Exp Clin Cancer Res. 2024 Nov 20;43(1):308.|J Nanopart Res. 2022; 24:261|J Proteome Res. 2022 Feb 16.|Life Sci. 2021 Feb 27;119239.|Mol Cancer Ther. 2018 Mar;17(3):603-613.|Mol Pharm. 2022 Oct 21.|Nat Commun. 2023 Apr 13;14(1):2110.|Nat Commun. 2023 Jun 15;14(1):3560.|Nat Immunol. 2018 Mar;19(3):233-245.|Nat Med. 2016 Jul;22(7):723-6.|Nature. 2017 Aug 24;548(7668):471-475. |Oncogene. 2016 Jun 9;35(23):2961-70. |Oncogene. 2022 May;41(22):3064-3078.|Oncotarget. 2017 Aug 24;8(62):104894-104912.|Oncotarget. 2020 Nov 3;11(44):3921-3932.|Open Life Sci. 2023, 18(1).|Patent. US20200108066A1|Patent. US20220305013A1.|Patent. US20240293405A1.|Personalized Medicine Universe. 2019 May. |PLoS One. 2019 Apr 4;14(4):e0214598.|RSC Adv. 2019, 9(34):19325-19332.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|Separations. 2023 May 26, 10(6), 330.|Stem Cell Reports. 2017 Dec 12;9(6):1948-1960.|Transl Oncol. 2022 Jul; 21: 101444.|Tumour Biol. 2016 Nov;37(11):14831-14839.|University of Gothenburg. 2023 Jun 27.|Harvard Medical School LINCS LIBRARY
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: Launched